Albatroz Therapeutics Joins Johnson & Johnson Innovation – JLABS Singapore to Accelerate Cancer Therapy Development

04 September 2024 | Wednesday | News


Albatroz gains access to JLABS' extensive mentorship and infrastructure, advancing its mission to develop targeted therapies for oncology and address critical unmet needs in cancer treatment.
Image Source : Public Domain

Image Source : Public Domain

Albatroz Therapeutics, a biotechnology company developing novel therapies against cancer and other indications, today announced its membership of Johnson & Johnson Innovation – JLABS Singapore.

"We are thrilled to join the vibrant life science community at JLABS," said Dr. Frederic Bard, CEO of Albatroz Therapeutics. "This membership provides Albatroz with invaluable access to mentorship, infrastructure, and industry connections that will be instrumental in propelling our groundbreaking therapies towards the clinic."

 

Albatroz Therapeutics is at the forefront of developing targeted therapies that address critical unmet needs in oncology. The company's lead programs focus on disrupting key pathways that result in tumor growth and metastasis. By joining JLABS Singapore, Albatroz gains access to a supportive ecosystem that will expedite the translation of its scientific discoveries into life-saving treatments for patients worldwide.

 

"We are confident that our membership with JLABS Singapore will significantly contribute to the success of Albatroz Therapeutics," Dr. Bard concluded. "We are committed to working diligently to bring our novel therapies to fruition and transform the landscape of cancer treatment."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close